Cysteamine Bitartrate
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inherited Mitochondrial Disease, Including Leigh Syndrome
Conditions
Inherited Mitochondrial Disease, Including Leigh Syndrome
Trial Timeline
May 1, 2014 → Oct 1, 2016
NCT ID
NCT02023866About Cysteamine Bitartrate
Cysteamine Bitartrate is a phase 2 stage product being developed by Amgen for Inherited Mitochondrial Disease, Including Leigh Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02023866. Target conditions include Inherited Mitochondrial Disease, Including Leigh Syndrome.
What happened to similar drugs?
0 of 1 similar drugs in Inherited Mitochondrial Disease, Including Leigh Syndrome were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02473445 | Phase 2 | Terminated |
| NCT02023866 | Phase 2 | Completed |
Competing Products
4 competing products in Inherited Mitochondrial Disease, Including Leigh Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Umbilical cord blood transplantation with HSC835 | Novartis | Phase 1/2 | 24 |
| PF-05089771 + Placebo | Pfizer | Phase 2 | 35 |
| BIIB074 + Placebo | Biogen | Phase 2 | 32 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 37 |